12:00 AM
Dec 10, 2012
 |  BioCentury  |  Finance

MorphoSys ventures in

Strategic fit of Lanthio's peptides triggers MorphoSys' first venture investment

MorphoSys AG (Xetra:MOR; Pink:MPSYF) is taking a page out of the playbook of Celgene Corp. (NASDAQ:CELG) by making a strategic investment in an early stage biotech.

Last month, MorphoSys participated in the €4.8 million ($6.2 million) series A round for Dutch peptide company Lanthio Pharma B.V. The round was co-led by existing investor BioGeneration Ventures and new investor INKEF Capital. New investor Hanzepoort also participated.

"We haven't put some money aside which we plan to invest, but if...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >